Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients
- 1 March 1988
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 24 (3) , 423-429
- https://doi.org/10.1016/s0277-5379(98)90012-8
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Adjuvant chemoendocrine therapy in breast cancer.Journal of Clinical Oncology, 1986
- Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.Journal of Clinical Oncology, 1986
- Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer.Journal of Clinical Oncology, 1985
- The Christie Hospital Tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma - 7-yr resultsEuropean Journal of Cancer and Clinical Oncology, 1985
- Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancerBreast Cancer Research and Treatment, 1985
- BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUESThe Lancet, 1985